by Chris Dokomajilar | May 23, 2023 | Analysis, Funding
The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...
by Chris Dokomajilar | May 3, 2023 | Analysis, Funding
The slowdown in interest rate hikes may increase small biotech companies’ initial public offerings (IPOs) later in 2023. Investors will be more cautious and favor firms with drugs in human trials. The biotech industry experienced a decline in IPOs globally in...
by Chris Dokomajilar | May 3, 2023 | Analysis, Funding
Biopharma IPOs as Investors Bet On Life-Saving Breakthroughs Only $400 million in 3 newly filed IPOs were raised in Q1 2023 – 1 fewer IPO filing compared to Q4 2022 but with a slightly higher value vs. $300 million raised in Q4 2022. Q2 of 2021 saw the most...
by Chris Dokomajilar | May 1, 2023 | Analysis, Funding
Venture capital investment activity in Q1 2023 was down across multiple industries, including biopharma. Biopharma venture fundraising looked much like 2022, which looked much like 2019. As before, biopharma fared slightly better than medtech, diagnostics, tools, and...
by Chris Dokomajilar | Apr 19, 2023 | Analysis, Funding, M&A, Partnership Deals
R&D Partnerships, M&A, Ventures, and IPOs by TA – Neurology The biotech industry is facing a critical moment as it enters 2023. The previous year was challenging for the sector, as initial public offerings decreased, and a biotech stock index declined by...
by Chris Dokomajilar | Apr 3, 2023 | Analysis, Funding, M&A, Partnership Deals
Deal Flow in 2022 Returned to pre-2019 Levels Lower Deal Dollars Across All Healthcare and Life Sciences Licensing Terms are Shifting to More in Milestones Large Cap Biopharma In-Licensing and Buying in 2022 Big...